Dr. Nellan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13123 E 16th Ave # B115
Aurora, CO 80045Phone+1 720-777-6740Fax+1 720-777-7226
Education & Training
- Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2013 - 2016
- University of Virginia Medical CenterResidency, Pediatrics, 2010 - 2013
- University of Arizona College of MedicineClass of 2010
Certifications & Licensure
- MD State Medical License 2013 - 2025
- CO State Medical License 2016 - 2021
- VA State Medical License Active through 2013
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 350 citationsCAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.Robbie G. Majzner, Johanna Theruvath, Anandani Nellan, Sabine Heitzeneder, Yongzhi Cui
Clinical Cancer Research. 2019-04-15 - 96 citationsDurable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cellsAnandani Nellan, Christopher Rota, Robbie G. Majzner, Cynthia M. Lester-McCully, Andrea Griesinger
Journal for Immunotherapy of Cancer. 2018-04-30 - 76 citationsImproved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.Anandani Nellan, Cynthia McCully, Rafael Cruz Garcia, Nalini Jayaprakash, Brigitte C. Widemann
Blood. 2018-08-09
Journal Articles
- Improved CNS Exposure to Tocilizumab After Cerebrospinal Fluid Compared to Intravenous Administration in Rhesus MacaquesBrigitte C Widemann, Daniel W Lee, Anandani Nellan, Blood
Press Mentions
- For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T CellsNovember 10th, 2020
Grant Support
- Effects of the immunosuppressive ependymoma (EPN) tumor microenvironment on anti-HER2 chimeric antigen receptor (CAR) T cellsNational Institutes of Health2018–2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: